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Abstract 
 
This paper addresses the mental decline and dementia of patients suffering from brain 
disorders. The most common of these neurological illnesses is Alzheimer’s disease, 
characterized by a progressive atrophy of cortical brain areas. Alzheimer’s disease accounts 
by far for the largest part of all dementias and is presently one of the most serious disorders, 
causing an immense burden on patients and society. Vascular dementia is noticed when the 
brain’s supply of blood is disrupted by strokes or other vessel pathologies and just as in 
Alzheimer’s this leads to cortical atrophy with almost identical symptoms. Since the 
distinction between Alzheimer’s and vascular dementia is a gradual one, mixed pathologies 
are rather common. Rarer causes of dementia are frontotemporal dementia, with pathologies 
mainly in frontal and temporal brain regions, Parkinson’s disease with atrophy in basal 
ganglia which leads to motor disturbances and at times to mental decline, Lewy body 
dementia caused by abnormal deposits in the brain resulting in considerable damages of 
neural cells, and Huntington’s disease, a genetic disorder with widely dispersed brain atrophy 
characterized by mixed Alzheimer’s and Parkinson’s symptoms. Presently, for the most part 
the cease of the progressive course of all these disorders is not possible. The last two 
disorders mentioned in this paper are normal pressure hydrocephalus, with a reduced 
absorption of ventricular fluid, and Korsakoff’s syndrome, caused by a deficiency of vitamin 
B1. In normal pressure hydrocephalus a brain shunt may reverse the pathological symptoms, 
while a vitamin B1 diet could improve the symptoms of Korsakoff’s syndrome. Diagnosis, 
symptoms and pathologies of all disorders are presented in this paper. 
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Abstrak 
 
Tulisan ini membahas penurunan mental dan demensia pada pasien yang menderita 
brain disorder. Penyakit paling umum dari penyakit neurologis adalah penyakit Alzheimer, 
ditandai dengan atrofi progresif area otak kortikal. Alzheimer menyumbang bagian terbesar 
dari terjadinya demensia dan saat ini merupakan salah satu gangguan yang paling serius, 
menjadi beban besar pada pasien dan Masyarakat. Demensia vascular terjadi ketika pasokan 
darah dalam otak terganggu oleh stroke atau patologi lain, seperti halnya Alzheimer ini 
menyebabkan atrofi kortikal dengan gejala yang hampir sama. Karena perbedaan antara 
Alzheimer dan demensia vaskular adalah bertahap, kombinasi dari patologi ini agak umum. 
Penyebab demensia yang jarang adalah demensia frontotemporal, dengan patologi terjadi 
utamanya di bagian otak frontal dan temporal, penyakit Parkinson dengan atrofi di ganglia 
basal yang menyebabkan gangguan motorik dan pada saat bersamaan terjadi penurunan 
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mental, Lewy body dementia disebabkan oleh deposit yang abnormal dalam otak yang 
mengakibatkan kerusakan sel saraf, dan penyakit Huntington, kelainan genetic yang tersebar 
luas pada atrofi otak ditandai dengan kombinasi Alzheimer dan gejala Parkinson. Saat ini, 
untuk menghentikan perkembangan progresif semua gangguan ini tidak mungkin. Dua 
gangguan terakhir dalam tulisan ini adalah normal pressure hydrocephalus, berkurangnya 
penyerapan cairan ventrikel, dan sindrom Korsakoff, yang disebabkan oleh kekurangan 
vitamin B1. Dalam normal pressure hydrocephalus, brain shunt dapat membalikkan gejala 
patologis, sedangkan diet vitamin B1 dapat meningkatkan gejala sindrom Korsakoff. 
Diagnosis, gejala dan patologi dari semua gangguan disajikan dalam tulisan ini. 
 
Kata kunci: brain disorder, dementia 
 
 
Dementia is not a specific disease. 
It is an overall term for a wide range of 
symptoms accompanying brain disorders 
causing a long-term and gradual decline in 
intellectual and or other cognitive 
functions. The essence of a dementia is a 
worsening of mental abilities, such as 
thinking, reasoning, insight, memory and 
executive functions, which is severe 
enough to reduce a person's performance 
in everyday activities. Side symptoms are 
often emotional and personality 
alterations, problems with language and a 
decrease in motivation. For diagnosis of 
dementia it is obligatory that the decline in 
the person's mental abilities is far greater 
than what could be expected due to ageing. 
In the DSM-5, dementia is classified as a 
cognitive disorder when more than one 
cognitive dysfunction is noted. The 
diagnosis is usually based on the history of 
the illness and on cognitive testing with 
brain imaging and somatic investigations 
in order to rule out other possible causes. 
The mini-mental state examination 
(MMSE) is a test generally used to screen 
cognitive impairments, indicating putative 
cognitive deficits, which have to be 
confirmed by neuropsychological 
assessments. The most common type of 
dementia is Alzheimer’s disease which 
makes up more than 50% of all dementias 
(Figure 1). Other types include vascular 
dementia and frontotemporal dementia. 
Less common types of dementia are 
Parkinson’s disease dementia, Lewy body 
dementia, Huntington’s disease, normal 
pressure hydrocephalus (NPH) and 
Korsakoff’s syndrome. More than one type 
of dementia may exist in the same person, 
whereby Alzheimer’s disease is often co-
occurring with other types of dementia, in 
particular with vascular dementia.  
 
 
 
Figure 1. Prevalence of types of 
dementia. Data are from the 
Framingham Study of Seshadri and 
colleagues (1997). The category ‘mixed 
Alzheimer’s’ consists mostly of patients 
with a mix of symptoms of both 
Alzheimer’s and vascular dementia. 
Lewy body dementia is in this graph 
presented under the category ‘mixed & 
others’, just as Huntington’s disease, 
syndrome of Korsakoff and normal 
pressure hydrocephalus.   
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Alzheimer’s Disease 
Alzheimer’s disease is the most common 
form of dementia and previously indicated 
as senile dementia. Alois Alzheimer 
(1864-1915) was a German psychiatrist 
who discovered and diagnosed the disease 
that bears his name now. Alzheimer had a 
practice in the University Psychiatric 
Clinic at Munich (Germany) under the 
famous psychiatrist Emil Kraepelin, the 
grandfather of schizophrenia. In 1901, 
Alzheimer examined patient Auguste 
Deter, a 51-years old woman with strange 
behavioral symptoms and a fast loss of 
short-term memory (Figure 2). Her 
condition rapidly deteriorated into a severe 
dementia. This patient was treated by 
Alzheimer for years and is now recognized 
as the first patient diagnosed with the 
disease of Alzheimer. In 1906, Auguste 
Deter died and the German neurologist 
performed autopsy on the patient’s brain. 
He identified a number of pathological 
conditions including shrinking of the 
cortex and the presence of neurotic plaques 
and neurofibrillary tangles (Figure 3). 
Plaques and tangles were distinctly enough 
to warrant a diagnosis of senile dementia 
which later become known as Alzheimer’s 
disease.
 
 
Figure 2. The German neurologist and psychiatrist Alois Alzheimer (1864-1915) (left) 
and his first patient Auguste Deter (1850-1906).  
 
Clinical Symptoms of Alzheimer’s 
Disease 
A common symptom in the early-
stage of Alzheimer’s is memory loss 
expressed in forgetting of recent obtained 
information. Also the ignorance of 
important dates or events, the over-and-
over asking for the same information are 
signs of an early stage of dementia. Family 
and friends begin to notice the memory 
difficulties, such as the forgetting of 
familiar words and the location of 
everyday objects. The short-term memory 
loss is the most obvious symptom of 
Alzheimer’s, but troubles with visual-
spatial orientation resulting in getting lost 
and problems with familiar tasks at home 
or at work, start also to appear. This early-
stage of Alzheimer’s is followed by the 
middle-stage in which reasoning, 
judgment, and insight deteriorates. This 
results in withdrawal from work and social 
activities. The patient becomes unable to 
recall his own address and telephone 
number, is confused about which day it is, 
needs help to choose proper clothing, and 
have trouble by controlling bladder and 
bowels. Changes in sleep patterns, such as 
sleeping during the day and restlessness at 
night can occur, just as an increased risk of 
getting lost. The personality of an 
Alzheimer patient might change. He can 
be frustrated or angry, moody or euphoric 
and often behaves in an unexpected way. 
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Suspiciousness and delusions with 
compulsive, repetitive behaviors such as 
hand-wringing, tissue shredding or 
continuous playing with small objects 
might occur. Many patients show the 
‘sundowning’ syndrome, an increased 
agitation with mood swings occurring in 
the late afternoon when the sun is setting. 
The middle-stage in Alzheimer is typically 
the longest stage and can last for many 
years. As the disease progresses, the 
person with Alzheimer's will require a 
great level of care. In the late-stage of the 
disease, patients lose the ability to respond 
to their environment, to carry on a 
conversation and, eventually, to control 
their movements. They may still utter 
words or phrases, but communicating is 
extremely difficult and finally impossible. 
As memory and other cognitive skills 
continue to worsen (especially executive 
functions), gross personality and 
behavioral changes take place and 
individuals need extensive help with all 
daily activities. In the late-stage patients 
require full-time, around-the-clock 
assistance with personal care. They need 
high levels of assistance with all activities. 
In this stage Alzheimer’s patients become 
increasingly vulnerable to the side-effects 
of the disease, such as to impairments of 
immune functions, to inability to ambulate, 
to incontinence and to aspiration. They 
often die suddenly as a consequence of 
these complications resulting in severe 
infections, especially in pneumonia. 
  
 
 
Figure 3. Left: The oldest picture of a cortex of a senile person published in 1898 by the 
Austrian neurologist Emil Redlich (1866-1930). Sclerotic plaques in the atrophied 
cortex of a senile individual with gross mental defects and confusions are shown in this 
photograph. Also some tangles can be identified. Right: The cerebral cortex of an 
Alzheimer patient showing a plaque and a tangle, the hallmarks of Alzheimer’s disease. 
A plaque is a sign of neuronal degeneration composed of the protein beta-amyloid, 
consisting of waste products of neurons and glia cells, axons and dendrites. Another 
waste product from degenerative structures within neuronal cell bodies are the twisted 
tangles from tau-protein. [Source: J.W. Kalat, Biological Psychology, Wadsworth, 
2009].    
 
Neuropathology of Alzheimer’s Disease 
The brain of a patient with 
Alzheimer’s disease commonly shows a 
marked atrophy, with widened sulci and 
shrinkage of the gyri. In the majority of 
cases, every part of the cerebral cortex is 
involved; however, the occipital pole is 
relatively spared, while the prefrontal 
cortex and the posterior parietal cortex are 
mostly affected. Also the inferior temporal 
cortex is widely attacked, due to atrophy of 
the hippocampus and to a lesser degree of 
the amygdala. Microscopically, there is 
shrinkage of cortical neurons, with a 
61 
 
significant loss of cells. The marked 
shrinkage of the dendritic trees of neurons, 
with a considerable loss of synapses, is the 
pathological substrate (Figure 4). Cell 
degeneration and loss lead to waste 
products as expressed in sclerotic plaques 
and fibrillary tangles (Figure 3). These 
pathological structures are regarded as the 
neurologic hallmarks of Alzheimer’s, 
although these lesions are not completely 
unique to Alzheimer’s. They can also be 
found in other neurodegenerative 
disorders, such as predominantly in the 
temporal lobes in semantic dementia, and 
even in healthy individuals, though in 
much less density. Classic neurotic 
plaques are spherical structures consisting 
of a central core of fibrous amyloid protein 
that is surrounded by degenerating nerve 
structures. Because beta-amyloid forms 
insoluble clumps in the brain, it has been 
postulated that they initiate a cascade of 
events leading to neuronal dysfunction and 
death. The accumulation of beta-amyloid 
is critical to the pathogenesis of 
Alzheimer’s. Neurofibrillary tangles are 
the other characteristic pathological 
changes seen in Alzheimer’s. Tangles are 
mostly found inside neurons and are 
composed of paired helical filaments of tau 
protein. Deposition may cause disruption 
of common neuronal architecture with 
subsequent neuronal cell death. Plaques 
and tangles are not evenly distributed 
across the cortex in Alzheimer’s, but are 
concentrated in vulnerable neural systems. 
The pathological criterion for the diagnosis 
of Alzheimer’s at autopsy requires the 
demonstration of a sufficient number of 
plaques and tangles on microscopic 
examination. Because of the presence of 
amyloid in plaques, the role of this protein 
and its precursor peptide (the amyloid 
precursor protein), is widely investigated, 
although the exact role in the pathogenesis 
of Alzheimer remains unclear. The most 
consistent biochemical change associated 
with Alzheimer’s has been the well-
documented decline in cholinergic activity 
that has inspired many attempts to treat 
this disease with cholinergic drugs.  
 
Figure 4. Brain atrophy in Alzheimer’s disease. Left: The cerebral cortex of a patient 
(a) has widened sulci and shrunken gyri in comparison with those of a normal person 
(b). Right: Atrophy is due to neuronal degeneration and cell loss. A cell in the prefrontal 
cortex of a normal brain (a). Cells from the same area of the cortex in Alzheimer’s 
disease at various stages of deterioration (b). Note the shrinkage of the dendritic tree. 
[Source: J.W. Kalat, Biological Psychology, Wadsworth, 2009].   
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Hypotheses Regarding Alzheimer’s 
Disease 
The oldest hypothesis of Alzheimer 
dementia is the cholinergic hypothesis 
(Bartus et al., 1982), and most drug 
therapies are still based on this hypothesis. 
The cholinergic hypothesis proposes that 
Alzheimer’s is caused by a reduced 
synthesis of the neurotransmitter 
acetylcholine. Decreased levels of 
acetylcholine in the brain are believed to 
be responsible for the typical symptoms of 
Alzheimer's disease. This hypothesis got 
an extra boost when publications appeared 
that smoking may prevent the development 
of Alzheimer’s. Later papers, however, 
made clear that smoking just doubles the 
risk on dementia, probably by the negative 
effects on blood vessels. This could mask 
the eventual positive effects of smoking by 
the stimulating effects of nicotine on the 
cholinergic system. The cholinergic 
hypothesis is the leading hypothesis but 
has not maintained general support, 
because medications intended to treat 
acetylcholine deficiency have not been 
very effective in Alzheimer’s. Medication 
is only delaying the deterioration and is 
not a cure of the disease. Despite this, 
almost all patients are treated with drugs 
increasing the level of acetylcholine. Two 
drugs are in use: galantamine and 
rivastigmine. Both belong to a class of 
drugs called cholinesterase inhibitors. 
These inhibitors block the action of 
acetylcholinesterase, the enzyme 
responsible for the destruction of 
acetylcholine. Galantamine and 
rivastigmine increase the concentration of 
acetylcholine in the brain by blocking the 
enzyme. The increase in acetylcholine is 
believed to be responsible for the 
improvement of symptoms of Alzheimer’s.  
In 1991, the amyloid cascade 
hypothesis (Hardy and Higgins, 1992) 
postulated that extracellular beta-amyloid 
deposits are the fundamental cause of the 
disease. Support for this postulate comes 
from the location of the gene for the 
amyloid precursor protein on chromosome 
21 and the apoE4 gene on chromosome 19. 
In particular, these two genes make people 
more risk full for the development for 
Alzheimer’s. Especially the apoE4 gene, 
synthesizing a specific isoform of 
apolipoprotein, is a major genetic risk 
factor. Scientists estimate that apoE4 is 
implicated in about 20 to 25 percent of late 
onset Alzheimer's. While most isoforms of 
these proteins enhance the breakdown of 
beta-amyloid, the apoE4 isoform is not 
effective in this process, leading to an 
excess of beta-amyloid in the brain. 
Further evidence is delivered by the 
finding that mice with a mutant form of the 
human amyloid precursor protein gene, 
develop amyloid plaques and a brain 
pathology reminding Alzheimer’s. The 
amyloid cascade hypothesis fails however 
to explain some aspects of Alzheimer’s, 
such as the poor correlation between 
plaque load and the degree of dementia. 
Therefore, an additional hypothesis, the 
tau-hypothesis (Braak and Braak, 1991), 
has been postulated that might fill this gap. 
This hypothesis proposes that tau-protein 
abnormalities precede the cascade of 
amyloid, since hyperphosphorylated tau 
begins early to pair with other threads of 
tau. Eventually, this leads to the formation 
of neurofibrillary tangles inside the nerve 
cell bodies. When this occurs, the 
microtubules disintegrate, destroying the 
structure of the skeleton of the neuron with 
a cascade of amyloid. This results in a 
malfunction in neurons and ends finally in 
the death of the cells.  
Oxidative stress may be significant 
in the formation of the pathology. Free 
radicals, mostly originating as by-products 
of the action of mitochondria in the cell, 
mediate oxidative cell injury and cell 
death. Mitochondrial oxidative 
phosphorylation is the major source of free 
radicals. The oxidative damage that 
ensues, attacks the structural and 
functional integrity of neurons. 
Alzheimer’s seems associated with a 
dysfunction of neurons due to free radical 
productions. Moreover, it is characterized 
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by a deficiency of antioxidant capacity. 
The free radicals thus are able to produce 
cellular damages unchecked by 
antioxidants. This is the ‘oxidative stress’ 
hypothesis of Alzheimer’s (Markesbery, 
1997). The use of antioxidants to limit the 
activity of free radicals as a therapy for 
Alzheimer's is extensively evaluated over 
the past decade. Perhaps the most widely 
studied is the antioxidant vitamin E, a 
candidate because of its powerful activity. 
Also vitamin D has been shown to have 
strong potencies as an antioxidant. Omega-
3 fatty acids are in use to attack the 
inflammation induced by the free radicals 
by strengthening the cellular membrane. 
All three substances, however, are not the 
ultimate panacea for Alzheimer’s disease.   
 
Living with Alzheimer’s Disease 
In all simplicity it can be stated that 
the affected cortical parts of the brain are 
responsible for the cognitive and mental 
defects and disorders, whereas the 
damaged hippocampus causes memory 
problems and the impaired amygdala 
induces the emotional swings. The changes 
in the brain start long before the first 
clinical signs such as short-term memory 
loss, are expressed. When clinical signs are 
noticeable, the affection of the brain is 
already in such an advanced stage that a 
therapy only can help in delaying the 
disease. Researchers hope to discover an 
easy and accurate way to detect 
Alzheimer's before irreversible brain 
damage has occurred. They believe that 
biological markers offer one of the most 
promising pathways. By using modern 
scanning techniques biomarkers such as 
the plaques (beta-amyloid level) and 
tangles (tau-protein level), indicating the 
presence of the disease can be identified in 
an early stage. Research on new strategies 
for an earlier diagnosis is among the most 
active areas in Alzheimer's science. 
Because early detection with biological 
markers on a structural level are not yet 
sensitive enough, diagnostic indicators 
focus on a functional neuropsychological 
level. A sensitive test to detect early 
dementia of the Alzheimer type is the 
Visual Association Test (VAT) of 
Lindeboom et al. (2002) (Figure 5). This 
test detects with high specificity a great 
proportion of patients with Alzheimer’s a 
year before the actual diagnosis can be 
achieved. A low score on this test is 
uncommon in patients with another type of 
dementia. 
 
 
Figure 5. The visual association test of Lindeboom and colleagues (2002), a brief 
learning task based on memory recall. The test materials consist of six familiar 
drawings (left part) shown to the person who has to name the objects. Secondly, each 
object is coupled to a non-associated other familiar object, for example, the ape now 
holds an umbrella. The six coupled pairs are presented again to the person who has to 
name now both objects of each pair (right part). Later, the six original single drawings 
are presented again to the person and now he has to name the associated objects of the 
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second presentation. A score of 2 or lower (maximum 6, which is a normal score for 
healthy persons) strongly points to Alzheimer’s.   
 
Life expectancy for Alzheimer 
patients vary for each patient, but the 
average life duration after diagnosis is 
approximately 10 years. In some cases, 
however, it can be as short as 3 years or as 
long as 20 years. There is a direct 
connection between brain abnormalities 
and the length of life. When cortex atrophy 
is too severe, e.g. when cortical thickness 
drops under 4 mm, death follows (Figure 
6, left part). Alzheimer’s can be 
undiagnosed for several years. In fact, the 
average length of time between the 
beginning of the early symptoms and the 
establishment of the diagnosis is estimated 
on 3 years. Alzheimer is an old people 
disease but it is not a normal part of 
ageing, although the greatest risk factor is 
increasing age (Figure 6, right part). The 
majority of people with Alzheimer's is 65 
or older. However, Alzheimer’s is not only 
a disease of old age since up to 5 percent 
of patients have early-onset Alzheimer's, 
often appearing when someone is in his 
early 40s or mid-50s. There are two 
categories of genes that are implicated in 
the development of Alzheimer’s (Bertram 
et al., 2010). The upper mentioned risk 
genes, such as the apoE4 gene, increase 
the likelihood of developing Alzheimer’s, 
although it is not certain that those people 
who have this gene will develop the 
disease. The estimation is that these risk 
genes are involved in about 20 to 25 
percent of late-onset Alzheimer's. The 
second category consists of the 
deterministic genes, which cause 
Alzheimer’s in everybody who inherited 
these genes. In a few hundred extended 
families these rare Alzheimer genes are 
found, which genes are responsible for 
these familiar early-onset Alzheimer 
forms.  
Worldwide there are more than 50 
million Alzheimer patients. A number that 
is fast increasing given the increase in the 
average age of humans. Alzheimer’s place 
a great burden on caregivers, especially 
given its debilitating and dehumanizing 
nature. Caring for someone with 
Alzheimer’s has a great impact on every 
aspect of the caregiver’s life. As a patient 
with Alzheimer’s loses one mental or 
physical ability after another, a caregiver 
faces tests of patience, problem solving 
and resiliency. Maintaining the emotional 
and physical fitness is crucial for 
caregivers. The continuous care makes that 
Alzheimer’s is a highly costly disease. It is 
estimated that almost half of the total 
nursing fees are for Alzheimer patients, 
due to the combination of the high costs 
for nursing and the lengthy stay of nursing. 
Medical society should make a major step 
forward in designing tests to predict a very 
early onset of the disease, facilitating the 
development of treatments which could 
prevent the progression of the disease.   
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Figure 6. Left: average life expectancy is about 10 years after diagnosis of Alzheimer’s 
or Alzheimer type dementia, mostly vascular dementia. Death comes when the 
atrophied cortex thickness is strongly reduced. Right: Global prevalence of Alzheimer’s 
disease in percentage as a function of age. From this graph it is evident that Alzheimer’s 
is an old people’s disease. Approximately 30% of people of 90 years show clear 
symptoms.  
 
 
Vascular Dementia   
Vascular dementia is characterized 
by a progressive decline in memory and 
cognitive functioning caused by a 
blockage or reduction in the blood flow to 
the brain. When the blood supply to the 
brain is interrupted by diseased vessels, 
brain cells are deprived of oxygen and 
vital nutrients, often causing damage to the 
cortex, the brain area which is involved in 
learning, memory and language. Vascular 
dementia is the second most common type 
of dementia after Alzheimer's disease, 
accounting for up to 40 percent of 
dementia cases in older adults. Depending 
on the person and the severity of the vessel 
obstruction, vascular dementia might start 
gradually but mostly more sudden and 
more stepwise compared to Alzheimer’s, 
and can range from mild to severe. 
Currently, there is no cure for vascular 
dementia, but there are steps to prevent 
vessel obstructions and strokes. Moreover, 
there are ways of living such as sufficient 
mental and physical activities, to 
compensate for cognitive losses, slowing 
the development of dementia. Vascular 
dementia is a heterogeneous entity with a 
large pathological spectrum consisting of 
cortical and subcortical ischemic damages 
resulting from local large- or small-vessel 
occlusions. Symptoms of vascular 
dementia include memory deterioration, 
though often less significant than in 
Alzheimer’s. Moreover, impairments in 
other cognitive domains, such as in 
language, executive functions and spatial 
orientation, may occur. Psychiatric 
disturbances such as depression and apathy 
are common in this type of dementia. The 
worsening of cognitive abnormalities 
might have a major impact on daily living 
of patients as well as on their family and 
caregivers. 
Epidemiological studies have 
recently established that vascular dementia 
and Alzheimer’s disease are more closely 
linked than was previously thought. 
Vascular dementia and Alzheimer’s share 
a number of vascular risk factors, 
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including atherosclerosis, high blood 
pressure and diabetes. Alzheimer patients 
have a higher risk for stroke, with about 30 
to 50 percent of Alzheimer’s displaying 
evidence of strokes at autopsy. The exact 
role of stroke in the disease of Alzheimer 
remains to be investigated. In any case 
vascular dementia and Alzheimer’s cannot 
be longer considered as strictly separated 
conditions. Mixed dementias with post-
mortem pathological evidence for both 
vascular dementia and Alzheimer’s seem 
much more common in the elderly than the 
pure forms of dementia. The clinical 
criteria to distinguish mixed dementia 
from vascular dementia and Alzheimer’s 
remain to be clearly defined. There is some 
evidence that cholinesterase inhibitors, 
such as rivastigmine and galantamine, may 
have a role in the treatment of vascular 
dementia. These agents have proven 
symptomatic efficacy in Alzheimer’s 
disease, and their use in vascular dementia 
has justification given the high prevalence 
of dementia with mixed pathologies. It is 
recommended to treat patients also for the 
cerebrovascular risk factors (Kirshner, 
2009). 
  
 
 
Figure 7. This is the legendary 
American boxer Muhammad Ali, born 
as Cassius Clay (1942-2016). Ali 
suffered from Parkinson’s disease which 
he got already at the end of his long 
boxing career. It is estimated that he got 
more than 25,000 punches to his head, 
while he fought without a helmet. The 
repeated blows caused multiple 
infarctions, leading to dementia 
pugilistica. It is still under discussion 
whether the disease of Parkinson he got, 
was the direct result of the trauma to 
the head causing the dementia or the 
medicines he got for that, or that it was 
just a fate that hit him The photo is 
taken from the Daily Mirror from 2014. 
 
A form of vascular dementia is 
known under the name multi-infarct 
dementia (Figure 7). This type of dementia 
is caused by a series of minor strokes. A 
stroke or infarction is the interruption or 
blockage of the blood flow to a part of the 
brain. Multi-infarct implies many small 
strokes with many, mostly small areas of, 
usually permanent, damage. A stroke can 
be ‘silent’. That means that it affects such 
a small area of the brain that it will not be 
noticed. Generally, a silent stroke is 
indicated as a ‘transient ischemic attack’ 
(TIA). Over time, many TIA’s may lead to 
multi-infarct dementia. Multiple infarcts 
and TIA’s are often the consequence of 
boxing. Boxing is a violent sport in which 
athletes accept the risk of brain damage. 
The most feared consequence of insults to 
the brain is multi-infarct dementia or 
dementia pugilistica (‘boxing’), now called 
‘chronic traumatic encephalopathy’ (CTE) 
(Saulle and Greenwald, 2012), the 
dementia which results from numerous 
small damages to superficial brain areas 
(Erlanger et al., 1999).    
 
Frontotemporal Dementia 
Frontotemporal dementia (FTD) 
occurs less often than other forms of 
dementia, such as Alzheimer’s disease or 
vascular dementia. However, it is a 
significant cause of dementia in younger 
people and is most often diagnosed in 
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people between the ages of 45 and 65. This 
is considerably younger than the age at 
which people are mostly diagnosed with 
the more common types of dementia. 
Frontotemporal dementia is probably the 
third most common cause for people in 
this age group. It affects men and women 
equally. FTD primarily affects the frontal 
and temporal lobes of the brain, the areas 
generally associated with personality, 
behavior and language (Weder et al., 
2007). Portions of these lobes atrophy or 
shrink (Figure 8) and signs and symptoms 
vary, depending upon the portion of the 
brain affected. Some people with 
frontotemporal dementia undergo dramatic 
changes in their personality and become 
socially inappropriate, impulsive or 
emotionally indifferent, while others lose 
the ability to use language. 
 
 
Figure 8. A PET scan can distinguish between different types of dementia. (A) a 55-
years old healthy control person, (B) a 60-years old patient with Alzheimer disease, the 
hypometabolism is most marked in the temporoparietal junction (TPJ), (C) a 50-years 
old patient with vascular dementia, with a more diffuse hypometabolism, (D) a 69-years 
old patient with frontotemporal dementia, with most marked hypometabolism in the 
frontal lobe. [Source: D. Linden, The Biology of Psychological Disorders, Palgrave, 
2012].  
 
Approximately 20 to 50 percent of 
frontotemporal dementia cases appear to 
be hereditary, meaning that a mutation in a 
specific gene is known to cause this type 
of dementia. Currently, mutations in six 
genes are known to be responsible for 
frontotemporal dementia. The most 
common genetic causes are mutations in 
the tau-gene and the progranulin-gene. Tau 
is the protein encoded by the MAPT gene. 
In patients with a mutation of this gene, 
the tau protein is altered and forms 
abnormal clumps in the brain. These 
alterations impair neuronal function, 
ultimately leading to cell death and 
disease. Tau clumps are also found in the 
brains of Alzheimer’s patients. Progranulin 
is a gene that, when mutated, also causes 
frontotemporal dementia. A mutation 
results in lowered levels of progranulin 
protein, and not having enough 
progranulin protein might cause the death 
of neurons in frontal and temporal lobes. 
How mutations in these genes can cause 
frontotemporal dementia is the focus of 
much research. The mutated genes provide 
the molecular handle needed to discover 
what goes wrong in the brains of 
frontotemporal dementia patients.  
 
Parkinson’s Disease Dementia 
Parkinson’s disease, previously 
known as paralysis agitans, is a 
degenerative disorder of the central 
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nervous system mainly affecting the motor 
system (Figure 9). The motor symptoms of 
Parkinson's disease result from the 
shrinkage and death of dopamine 
generating cells in the substantia nigra, a 
part of the basal ganglia. The basal ganglia 
are located in the midbrain. The cause of 
this midbrain cell degeneration is poorly 
understood, but it is known that alpha-
synuclein clumps are likely to begin in the 
substantia nigra and these clumps are 
thought to cause degeneration of the nerve 
cells that produce dopamine (Shulman et 
al., 2011). The most obvious clinical 
symptoms are movement related, including 
shaking and tremor, muscle rigidity, 
slowness of movements and speech, and 
difficulties with walking and gait. Later 
on, behavioral problems such as irritability 
and anxiety may arise, whereas depression 
is also a common symptom. Trouble of 
interpreting visual information with 
hallucinations, delusions and paranoid 
ideas are also arising. Other symptoms 
include concentration problems and sleep 
disorders, such as nightly sleeplessness, 
excessive daytime drowsiness and REM-
sleep disorder. Parkinson's disease is more 
common in older people, with most cases 
occurring after the age of 50 to 60. When it 
is seen in young adults, it is called young 
onset Parkinson’s disease.
  
 
 
Figure 9. Left: in Parkinson's disease a slowing down of movements in conjunction with 
rigid muscles, a mask-like face, and trembling of head and extremities may be noticed. 
A forward tilted posture is also one of the symptoms, in order to prevent falling since 
the affected person has difficulties in maintaining body balance. Right: James 
Parkinson (1755 - 1824) an English surgeon, geologist, and political activist, is most 
famous for his 1817 work, ‘An Essay on the Shaking Palsy’, in which he was the first to 
describe ‘paralysis agitans’, a condition that later was renamed Parkinson’s disease. 
 
A person with Parkinson’s disease 
has two to six times the risk of dementia 
compared to the general population. The 
prevalence of ‘Parkinson’s disease 
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dementia’ increases with the duration of 
the disease. Regardless of age at onset of 
Parkinson’s disease, dementia symptoms 
tend to appear after about 10 to 15 years, 
In the advanced stages of the illness an 
estimated 50 percent of Parkinson patients 
experience dementia symptoms. Dementia 
is associated with a reduced quality of life 
in people with Parkinson’s disease and 
their caregivers, with increased mortality, 
and with a higher probability of needing 
nursing care at home. As Parkinson's 
disease progresses, it often results in a 
progressive dementia similar to the 
dementia seen in Alzheimer's.   
 
Lewy Body Dementia   
Lewy body dementia is a type of 
progressive dementia that leads to a 
decline in thinking, reasoning and 
malfunctioning because of abnormal 
microscopic deposits that damage brain 
cells. Dementia with Lewy bodies which 
originally was considered as a rare form of 
dementia, is presently the fourth common 
cause of dementia after Alzheimer’s 
disease, vascular dementia and 
frontotemporal dementia. This is due to the 
fact that symptoms become more and more 
obvious. The hallmark brain abnormalities 
linked to this type of dementia are the 
Lewy bodies (Figure 10) (McKeith, 2002). 
These are named after the German-born 
neurologist Friedrich H. Lewy, a colleague 
of Alois Alzheimer. He discovered these 
structures while working in Dr. Alois 
Alzheimer's clinic during the early 1900s. 
Alpha-synuclein protein, the major 
component of Lewy bodies, is found 
widely in the brain, but its normal function 
is yet not known. Lewy bodies are also 
found in other brain disorders, including 
Alzheimer’s and Parkinson’s disease. 
Lewy body dementia is closely related to 
Parkinson’s disease dementia. One of the 
differences is in the location of the Lewy 
bodies: in Lewy body dementia they are 
more found in cortical areas, and in 
Parkinson’s dementia in subcortical areas.  
 
 
Figure 10. The key brain changes linked 
to dementia with Lewy bodies are 
abnormal microscopic deposits 
composed chiefly of alpha-synuclein, a 
protein that is found widely in the brain 
but whose normal function is not yet 
known. The deposits are called ‘Lewy 
bodies’. [Source: J.M. Ellison, ‘National 
Library of Medicine’ (NHI), USA, 
2013].  
  
Many people with Lewy body 
dementia experience movement symptoms 
reminding Parkinson’s disease, such as 
hunched posture, rigid muscles, a shuffling 
walk and trouble initiating movements. 
The memory loss tends to be a more 
prominent symptom in early Alzheimer's 
than in early Lewy body dementia, 
although in an advanced stage memory 
problems are considerable, in addition to 
the more typical Lewy body effects on 
judgment, planning and visual perception. 
Movement symptoms are more likely to be 
an important cause of disability in early 
Lewy body dementia than in Alzheimer's. 
Also hallucinations, delusions, REM-sleep 
disorders and misidentifications of familiar 
people (‘Capgras-syndrome’) are 
significantly more frequently occurring in 
early-stage dementia with Lewy bodies 
than in Alzheimer's. Also disruption of the 
autonomic nervous system, causing a 
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blood pressure drop on standing, dizziness, 
falls and urinary incontinence, is more 
common in early dementia with Lewy 
bodies. The diagnosis of dementia with 
Lewy bodies is done when dementia 
symptoms consistent with this type of 
dementia develop first or when both 
dementia symptoms and movement 
symptoms are present approximately at the 
time of diagnosis. In fact, Lewy body 
dementia has traits both from Parkinson’s 
and Alzheimer’s disease. Medication is 
done with low doses of levodopa to 
increase dopamine in the basal ganglia, 
while the confusions and hallucinations of 
Lewy body dementia are treated with 
cholinesterase inhibitors used in 
Alzheimer’s, such as rivastigmine and 
galantamine. 
 
Huntington’s Disease  
Huntington’s disease is an 
autosomal dominant neurodegenerative 
disorder. This implies that each child of an 
affected parent has fifty percent chance of 
developing the disease. This is due to an 
abnormal expansion of the IT-15 gene on 
the arm of chromosome 4, which gene 
encodes for the protein huntingtin. Most 
people develop Huntington’s disease 
between an age of 30 to 50 years old, 
although it can manifest itself on a much 
younger or much older age. It is a 
progressive disorder and death can follow 
between fifteen and twenty years after 
onset. Huntington’s disease is rare with a 
worldwide prevalence of five to ten cases 
per 100.000 persons. The occurrence is 
highest in West-Europe and lower in the 
rest of the world. Prevalence is similar for 
men and women.  
 
 
 
 
 
Figure 11. Left: a patient with 
Huntington’s disease. Note the 
characteristic, chorea–like hand 
movements. The photo is taken from R. 
van Hes: ‘Dansen aan Zee’, (‘Dancing at 
Sea’), Katwijk, NL, 2006. Right: the 
human brain showing the impact of 
Huntington’s disease. The affected brain 
is shown at the bottom and a normal 
brain on top. Brain atrophy is expressed 
in an expansion of the cerebral 
ventricles (in black), due to the loss of 
cerebral neurons. Affection is most 
extensive in the region of the basal 
ganglia and cortex. [Source: N.R. 
Carlson, Physiology of Behavior, Allyn 
& Bacon, 2010].  
 
 
Huntington’s disease is clinically 
characterized by a triad of motor, cognitive 
and psychiatric symptoms (Roos, 2010). 
Motor features include an impairment of 
movements, reduced manual skills, slurred 
speech, difficulties with swallowing, and 
problems with keeping balance associated 
with falls (Figure 11). Psychiatric features 
include mood disorders (particularly 
depressive episodes), obsessive-
compulsive behavior, and social 
withdrawal. Cognitive features are initially 
characterized by a loss of speed and 
flexibility in thinking, but become later 
more global, expressed in progressive 
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impairments. Especially affected are 
executive functions including planning, 
cognitive flexibility, initiation of 
appropriate actions, and inhibition of 
inappropriate movements. As the disease 
progresses, memory deficits tend to 
appear. Reported impairments range from 
working memory to long-term memory 
deficits. Cognitive problems tend to 
worsen over time, leading to dementia. In 
a post-mortem examination of the brain a 
reduction in brain size is found of up to 20 
percent. Neuronal loss is found in the basal 
ganglia, the globus pallidus, the 
cerebellum and the cortex (Figure 11). The 
earliest loss is seen in the striatum of the 
basal ganglia, where up to 95 percent of, 
particularly GABAergic, neurons is lost in 
advanced cases. Huntington’s disease can 
be regarded as having traits both from 
Alzheimer’s and Parkinson’s disease, in 
addition the disorder is characterized by its 
typical jerky movements.   
Huntington’s disease is also called 
Huntington’s chorea. The term ‘chorea’ is 
derived from the Greek word for ‘dance’, 
as the most characteristic jerky, 
uncontrollable movements of feet and 
hands are comparable to ‘dancing’. They 
can affect various body parts, and interfere 
with speech, swallowing, posture and gait. 
Chorea may worsen with anxiety and 
voluntary movements, and subsides during 
sleep. Severe choreiformic movements 
appear to be wild, violent, and can involve 
flinging of a body part, inducing 
injuries. Presently, there is no cure for 
Huntington’s disease. Nevertheless, non-
pharmacological approaches to functional 
difficulties and behavioral dysfunctions in 
Huntington’s disease are important. 
Dopamine receptor blocking agents can be 
used if the chorea is seriously disrupting 
quality of life. Examples of agents used to 
alleviate chorea include reserpine and 
neuroleptics such as haloperidol and 
risperidone. Deep brain stimulation for 
severe and disabling cases of Huntington’s 
chorea have already been reported. 
Normal Pressure Hydrocephalus 
The name ‘normal pressure 
hydrocephalus’ (NPH) is a typical 
misnomer since the pressure in the brain is 
higher than normal. In NPH the increase in 
intracranial pressure is due to an abnormal 
accumulation of cerebrospinal fluid in the 
ventricles of the brain due to a decreased 
absorption of this fluid. This can cause an 
enlargement of the vesicles. This 
ventricular enlargement is putting an 
increased pressure on the adjacent cortical 
tissues, causing the typical multiple NPH 
effects in the patient. Normal pressure 
hydrocephalus can occur in people of 
every age, but is most common in the 
elderly. It might result from a hemorrhage, 
from a head trauma or from a brain tumor, 
but people may develop NPH even when 
none of these factors is present. In these 
case the cause of the disorder is unknown. 
The three most typical symptoms of NPH 
are gait disturbances associated with 
walking problems, impaired bladder 
control with urinary incontinence, and a 
progressive mental slowing and 
inattentiveness associated with dementia 
(Figure 12). The patient might also have a 
general slacking up of his movements. 
Because these symptoms are similar to 
those of disorders such as Alzheimer's 
disease and Parkinson's disease, NPH is 
often misdiagnosed. The classic 
symptomatic triad of gait disturbance, 
urinary incontinence and dementia was 
first described by Adams and colleagues in 
1965. 
Treatment for NPH involves the 
surgical placement of a shunt in the brain 
to drain the excess of cerebrospinal fluid 
into the abdomen (Figure 12). This allows 
the brain ventricles to return to their 
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normal size. Regular follow-up care by a 
physician is important in order to identify 
subtle changes that might indicate 
problems with the shunt. The shunt 
treatment can reverse the symptoms and 
restore normal functioning in 
approximately 50 percent of cases, or it 
may do so partially, or it may not succeed 
at all. The reasons for sometimes not 
improving the symptoms of NPH with a 
shunt are yet not known. If NPH is not 
treated its symptoms get worse over time, 
although some people may experience a 
temporary improvement. While the 
success of treatment with shunts varies 
from person to person, some patients 
recover almost completely after treatment 
and have a good quality of life. Early 
diagnosis and treatment improves the 
chance of a good recovery. Without 
treatment, symptoms generally become 
more worst and may rarely cause the death 
of the patient.  
 
 
 
 
 
Figure 12. Left: a patient with normal pressure hydrocephalus (NPH), characterized by 
an abnormal gait, urinary incontinence and dementia. Middle: the enlarged ventricles 
of the patient’s brain. Right: a ventricular catheter is installed in the lateral ventricle of 
the brain. The superfluous cerebrospinal fluid is drained into the peritoneal cavity of 
the abdomen. The left drawing is from Frank H. Netter and taken from ‘The Ciba 
Collection of Medical Illustrations’ (1986).  
 
Recent population-based studies 
have estimated the prevalence of NPH to 
be about 0.5% in those over 65 years old, 
with an incidence of about 5.5 patients per 
100.000 persons per year. Although NPH 
can occur in both men and women of every 
age, it is found more often in the elderly, 
with a common onset between 60 and 70 
years of age.  
Korsakoff’s Syndrome 
Korsakoff’s syndrome is a chronic 
memory disorder caused by prolonged and 
severe deficiency of vitamin B1, also 
named thiamine. The syndrome is most 
commonly induced by alcohol misuse, but 
other conditions, such as poor nutrition 
may also lead to this syndrome. The name 
giver of the syndrome is the Russian 
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physician Sergei Korsakoff who performed 
detailed studies towards alcoholic memory 
impairments (Figure 13). It is yet not 
known why heavy, prolonged drinking 
causes severe thiamine deficiency in some 
alcoholics, though alcoholics often suffer 
from malnutrition in addition to the fact 
that alcohol obstructs the uptake of 
thiamine. Thiamine helps brain cells to 
produce energy from sugar and when 
thiamine levels are too low, neurons 
cannot generate enough energy to function 
in a proper way. Brain cell atrophy occurs 
particularly around the mammillary bodies 
in the hypothalamus, near the 
hippocampus, and regions of the thalamus 
and the frontal lobe (Kopelman, 2015). 
This leads to the clinical symptoms of 
Korsakoff’s syndrome with memory 
losses, confusions and confabulations.   
 
Figure 13. In 1889, Sergei Korsakoff 
(1854-1900) a Russian physician who 
first described the severe memory 
impairments caused by brain damages 
and mostly appearing in alcoholics. 
Later this disorder was given the name 
‘Korsakoff’s syndrome’.  
 
The amnesia that accompanies 
Korsakoff’s syndrome can extend as far 
back as twenty to thirty years, while old 
memories are recalled better than more 
recent ones. Both anterograde and 
retrograde amnesia can be found in the 
syndrome (Kessels and Kopelman, 2012). 
It has been widely accepted that the critical 
structures that lead to the memory 
impairments in Korsakoff’s syndrome are 
the mammillary bodies and the thalamic 
and frontal regions. There is also a gradual 
degeneration of the patient’s mental state, 
consisting of confusions, hallucinations 
and confabulations. In particular people 
with Korsakoff’s syndrome often show 
confabulations, incorrect memories that 
the patient holds to be true. Korsakoff 
patients tend to make up stories about past 
events rather than to admit that they 
actually do not remember what happened. 
Patient’s stories are generally plausible 
because they are loosely based on real 
experiences while the patient self believes 
in his stories. Confabulations are rather 
typical for this form of dementia. 
Symptoms of Korsakoff dementia are 
essentially the same as the symptoms 
present in other types of dementia, making 
this form of dementia difficult to diagnose. 
Patients with Korsakoff dementia may 
develop memory problems, language 
impairments, and an inability to perform 
complex motor tasks, such as dressing 
themselves. Patients may also develop 
apathy, irritability, and resistance. It can 
occur that people who have Korsakoff-
related dementia may have a good verbal 
intelligence, while their language skills 
might be rather good preserved. A 
comparison between Alzheimer’s 
dementia and Korsakoff’s dementia shows 
in general no qualitative, but only 
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quantitative differences. The degree of the 
severity of the dementia in Korsakoff 
might be less serious compared to other 
forms of dementia, such as Alzheimer’s 
and vascular dementia. Recovery with a 
vitamin B1-enriched diet is possible in 
approximately 20 percent of Korsakoff 
patients. Most patients, on the other hand 
spend the rest of their lives in nursing 
homes or clinical settings. 
 
Epilogue  
Dementia is not a single disease but 
a collective designation for problems that 
patients experience with their cognitive 
functions, such as intellect, memory, 
speaking and language. Alzheimer’s 
disease is the best known under the 
dementias. All dementias are caused by 
brain impairments and in particular by 
degeneration of the brain by a progressive 
cell loss. The main risk factor for acquiring 
brain disorders leading to dementia is 
ageing, although it is not a regular part of 
this process. Compared to normal ageing 
abnormal neuronal cell loss causing 
cognitive impairments is exceptional fast. 
Since it is impossible to avoid ageing and 
since the number of older people grow 
rapidly due to a general age increase, it is 
inevitable that the number of patients with 
various types of dementia, in particular 
with Alzheimer’s disease, will show an 
extensive increase. To keep this rapidly 
growing problem under a relative control 
the medical and neuropsychological 
society must be provided with sensitive 
screening and diagnostic techniques to 
identify dementias in an early stage. In the 
beginning development of the behavioral 
symptoms of dementia are not manifest 
implying that brain damage is still 
relatively small. With valuable clinical 
practice early indications of beginning 
dementia can be detected and the braking 
of a further progress of brain degeneration 
seems than not impossible. Brain scientists 
and neuropsychologists have further the 
challenging task to identify the factors 
playing a role in the degenerative atrophic 
process. Knowing the key processes 
leading to neuronal cell loss and death is a 
major step forward in the development of a 
treatment or a final therapy for dementia. 
Both neurophysiologists and 
neuropsychologists have so a major 
responsibility in discovering effective 
remedial treatments for brain impairments 
but also for improving the quality of life 
for individuals with dementia.   
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